NCT05717920Phase 2Completed

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Study sponsor: Aldeyra Therapeutics, Inc. · ALDX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-11-21Actual
Enrollment · participants8Actual
Source updated2026-11-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Adverse Event (AE) Query Description: Incidence and severity of AEs Time frame: From Day 1 to Day 90. After: Measure: Number of Subjects With Serious Adverse Events Description: The proportion of subjects that experience at least one serious adverse event Time frame: The safety assessment period was approximately 15 weeks..

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview